Zobrazeno 1 - 10
of 66
pro vyhledávání: '"W S, Velasquez"'
Autor:
Sundar Jagannath, Jorge A. Spinolo, W. S. Velasquez, L. J. Horwitz, Karel A. Dicke, Fredrick B. Hagemeister, Fernando Cabanillas, Gary Spitzer
Publikováno v:
Leukemia & Lymphoma. 9:71-77
The use of high-dose cyclophosphamide, carmustine, and etoposide (CBV) with autologous bone marrow transplantation (ABMT) results in long-term disease-free survival of about 30% in patients with relapsed Hodgkin's disease. Laboratory and clinical dat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::864f1e3f51fa9c0181c1e2e4bba1e684
https://doi.org/10.3109/10428199309148506
https://doi.org/10.3109/10428199309148506
Autor:
Fredrick B. Hagemeister, W. S. Velasquez, Peter McLaughlin, John R. Redman, Fernando Cabanillas
Publikováno v:
Scopus-Elsevier
After completing chemotherapy and achieving a complete remission (CR), patients with diffuse intermediate-grade lymphoma and immunoblastic lymphoma are usually considered cured if they are able to maintain that remission continuously for 24 months. R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe671424330846d2beb8004082797ce8
https://doi.org/10.1182/blood.v79.4.1024.1024
https://doi.org/10.1182/blood.v79.4.1024.1024
Autor:
M. Alma Rodriguez, Shiao Y. Woo, Peter McLaughlin, Melissa L. Bondy, Fredrick B. Hagemeister, Jackson Cundiff, Pamela K. Allen, F. Swan, W. S. Velasquez, Fernando Cabanillas, Lillian M. Fuller, Robert J. Carpenter
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 23:407-412
Between 1956 and 1990, 775 women were treated for Hodgkin's disease at The University of Texas M.D. Anderson Cancer Center. Of these, 25 (3.2%) were pregnant at diagnosis. Seven of these women were in the first trimester, 10 in the second, and eight
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9aa19f042f73d9d356844dbd5941bcc3
https://doi.org/10.1016/0360-3016(92)90761-6
https://doi.org/10.1016/0360-3016(92)90761-6
Autor:
Gary Spitzer, DD Weisenburger, Dominique Bron, Thierry Philip, James O. Armitage, Pierre Biron, Franck Chauvin, Anton Hagenbeek, W. S. Velasquez, J Fernandez-Ranada
Publikováno v:
Blood. 77:1587-1592
Fifty patients with intermediate- or high-grade non-Hodgkin's lymphoma (NHL) who had relapsed after a complete remission induced by an Adriamycin-containing chemotherapy regimen participated in this prospective pilot study. The patients ranged in age
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20ea37529b0cf00376efc990b4d89da3
https://doi.org/10.1182/blood.v77.7.1587.bloodjournal7771587
https://doi.org/10.1182/blood.v77.7.1587.bloodjournal7771587
Autor:
Peter McLaughlin, Sundar Jagannath, John R. Redman, Maria A Rodriguez, Luceil B. North, Fredrick B. Hagemeister, F. Swan, Fernando Cabanillas, Lillian M. Fuller, W. S. Velasquez, Susan L. Tucker
Publikováno v:
Blood. 77:942-947
One hundred forty-seven patients with Ann Arbor stages I and II diffuse large cell lymphoma (DLCL) were treated with combination chemotherapy consisting of cyclophosphamide, doxyrubicin, prednisone, and low-dose bleomycin (CHOP-Bleo) and involved-fie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a732fbc563145a97c8e1c287a335a44
https://doi.org/10.1182/blood.v77.5.942.942
https://doi.org/10.1182/blood.v77.5.942.942
Autor:
F. Swan, Fernando Cabanillas, Fredrick B. Hagemeister, Lillian M. Fuller, L. Holmes, E. Durr, Pamela K. Allen, Peter McLaughlin, John R. Redman, W. S. Velasquez
Publikováno v:
Annals of Oncology. 2:137-140
Between 1984–1989, 44 patients with stage I–II low grade lymphoma were treated prospectively with sequential chemotherapy and involved-field radiotherapy. The chemotherapy was cyclophosphamide, vincristine, prednisone, and bleomycin (COP-Bleo); d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbd3f08c9db00bbb95701d65dd87905c
https://doi.org/10.1093/annonc/2.suppl_2.137
https://doi.org/10.1093/annonc/2.suppl_2.137
Autor:
Jorge E. Romaguera, Peter McLaughlin, W. S. Velasquez, Fredrick B. Hagemeister, Lillian B. Fuller, Karen B. Silvermintz, Fernando Cabanillas
Publikováno v:
Cancer. 66:267-272
Tumor burden is an important predictor of survival in patients with diffuse large cell lymphoma (DLCL). The authors reviewed the charts of 147 patients with early stage presentation (Stage I-IE and II-IIE) seen from 1974 through 1984. The 10-year sur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a69ad17698249b5f641a1514168cd4bb
https://doi.org/10.1002/1097-0142(19900715)66:2<267::aid-cncr2820660213>3.0.co
https://doi.org/10.1002/1097-0142(19900715)66:2<267::aid-cncr2820660213>3.0.co
Publikováno v:
Journal of Clinical Oncology. 8:266-271
Thirty-four patients with stages IE and IIE gastric lymphoma were treated with chemotherapy and radiotherapy combinations without stomach resection. In 20 patients, the diagnosis was established by endoscopic biopsy only; the other 14 had laparotomy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b0d9b3ff927640a580ce97c94c44825
https://doi.org/10.1200/jco.1990.8.2.266
https://doi.org/10.1200/jco.1990.8.2.266
Autor:
M. S. Lucas, Brian K. Link, Christine A. White, Antonio J. Grillo-Lopez, W. S. Velasquez, John C. Byrd, Jay Rosenberg
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 10(12)
To assess the preliminary efficacy of rituximab therapy in Waldenstrom's macroglobulinemia (WM), we examined the clinical and laboratory data for all patients with WM treated on IDEC Pharmaceuticals sponsored trials and one patient treated at Walter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd2c5e444a24b966560f37f5f5ea615c
https://pubmed.ncbi.nlm.nih.gov/10643548
https://pubmed.ncbi.nlm.nih.gov/10643548
Autor:
R. Weaver, C.A. White, Thomas A. Davis, Brian K. Link, S. Dowden, W. S. Velasquez, Antonio J. Grillo-Lopez, David G. Maloney, Michael E. Williams, Ronald Levy, Robert O. Dillman, Ann Mohrbacher
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 17(6)
PURPOSE: A phase II trial was performed to evaluate the safety and efficacy of rituximab, a chimeric anti-CD20 monoclonal antibody, in patients with bulky (> 10-cm lesion) relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (NHL). P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62609748732fa947a8260154d2c18593
https://pubmed.ncbi.nlm.nih.gov/10561225
https://pubmed.ncbi.nlm.nih.gov/10561225